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SUMMARY
Polymyalgia rheumatica (PMR) is a chronic, inflammatory disorder of unknown cause, almost exclusively 
occurring in people aged over 50 and often associated with giant cell arteritis. The evidence that PMR occurs 
almost exclusively in individuals aged over 50 may indicate that age-related immune alterations in genetically 
predisposed subjects contribute to development of the disease. Several infectious agents have been investigated 
as possible triggers of PMR even though the results are inconclusive. Activation of the innate and adaptive 
immune systems has been proved in PMR patients as demonstrated by the activation of dendritic cells and 
monocytes/macrophages and the altered balance between Th17 and Treg cells. Disturbed B cell distribution 
and function have been also demonstrated in PMR patients suggesting a pathogenesis more complex than previ-
ously imagined. In this review we will discuss the recent findings regarding the pathogenesis of PMR.
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n	 INTRODUCTION
Polymyalgia rheumatica (PMR) is a chronic, inflammatory disorder of un-
known cause almost exclusively occurring in 
people aged over 50 (1-3). PMR is clinically 
characterised by the acute or subacute onset 
of pain and stiffness in the neck, shoulders, 
hips, upper arms, and thighs (3, 4). A very 
strong association has been demonstrated 
between PMR and giant cell arteritis (GCA) 
(5-7), a systemic, granulomatous vasculitis 
mainly affecting the aorta and its branches 
(8). Although the pathogenesis of GCA has 
been extensively studied, the pathogenic 
mechanisms underlying PMR are less clear-
ly defined. The evidence that PMR occurs al-
most exclusively in individuals aged over 50 
years may indicate that, similarly to GCA, 
age-related immune alterations in geneti-
cally predisposed subjects contribute to the 
development of the disease (9, 10). In this re-
view we will discuss recent findings regard-
ing the pathogenesis of PMR (Figure 1).
n	 IMMUNOGENETICS
Several studies have reported an asso-
ciation between the disorder and spe-
cific polymorphisms in genes related to 
immune regulation. HLA class II histo-
compatibility antigen, DRB1 beta chain 
is a protein that is encoded in humans 
by the HLA-DRB1 gene. Several alleles 
of DRB1 (shared epitope alleles) are as-
sociated with an increased incidence of 
joint inflammation as seen in rheumatoid 
arthritis (11). 
The association between HLA-DRB1 
genotypes and susceptibility to polymy-
algia rheumatica is controversial. Unlike 
PMR associated with GCA, which is gen-
erally associated with HLA-DRB1*04 
alleles, the HLA-DRB1 susceptibility to 
isolated PMR varies in different popula-
tions (9, 12). The association between 
HLA-DRB1*04 alleles and isolated PMR 
has been suggested by Salvarani et al., 
who reported a high incidence of HLA-
DR1 among their Italian patients with 
isolated PMR (13). In addition, Gonzalez 
Gay et al. have suggested a possible in-
fluence of HLA-DRB1*04 alleles in the 
development of more severe disease with 
a more pronounced synovial inflammation 
in patients from the North-western Spain 
(4, 14). The inflammation of sub-acromial 
and sub-deltoid bursa in PMR patients 
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suggests that cytokines involved in the in-
flammatory process may play a role in the 
pathogenesis of the disease. In this regard, 
PMR has been demonstrated to be associ-
ated with different TNF polymorphisms. 
Isolated PMR in patients from Lugo, 
North-western Spain, has been in fact 
positively associated with TNF-b3, inde-
pendently of the HLA-class II association, 
and negatively associated with TNF-d4 
(15). Beyond TNF, the genetic contribu-
tion of other pro-inflammatory cytokines 
has been studied in PMR patients. The 
IL-1RN*2 allele, particularly when ho-
mozygous, is associated with increased 
susceptibility to PMR and the IL-6 pro-
moter polymorphism is associated with 
biopsy-proven GCA patients with PMR 
manifestations in Italian patients (16, 17). 
The TLR9 Thr399Ile CC genotype has 
been associated with a higher cumulative 
dose of corticosteroids in Spanish patients 
with PMR (18, 19). 
Genetic polymorphisms associated with 
PMR risk or severity in Italian patients 
include intercellular adhesion molecule 1, 
interleukin 1 receptor antagonist, and in-
terleukin 6 (16, 17, 20).
n	 INFECTIOUS AGENTS
The hypothesis has long been considered 
that in a genetically predisposed patient, 
an environmental factor, possibly a vi-
rus, may induce monocyte and dendritic 
cell activation and the production of 
pro-inflammatory cytokines that induce 
manifestations characteristic of PMR (21, 
22). However, although several infectious 
agents have been investigated as possible 
triggers, the results are inconclusive. The 
synchronous variations in the incidences 
of PMR recorded in Denmark strongly 
indicate that an environmental infectious 
factor may influence the frequency of the 
disease (23). In this regard, Elling et al. 
demonstrated a close concurrence with 
epidemics of M. pneumoniae and the co-
incidence of 2 epidemics of parvovirus 
B19 and of one epidemic of C. pneu-
moniae. Additionally, in studies from the 
UK and Italy, PMR occurred more often 
during summer months than during winter 
months (24). In a different cohort of pa-
tients, however, onset of PMR symptoms 
was unrelated to seasonal pattern with 
50% of cases occurring in the months of 
May, February, and August. Cimmino et 
al. demonstrated that antibodies to ad-
enovirus (ADV) and respiratory syncy-
tial virus (RSV) were significantly more 
prevalent in PMR patients, suggesting that 
ADV and RSV might be the possible mi-
croorganisms responsible for triggering 
PMR in elderly people (24). Although a 
few studies reported the presence of an 
association between parvovirus B19 and 
PMR, the results have been not replicated 
in larger studies (21, 25). Finally, no role 
of current or previous hepatitis B virus 
infection has been demonstrated in the 
pathogenesis of the majority of cases of 
polymyalgia rheumatic (26).
Figure 1 - Pathogenic mechanisms in polymyalgia rheumatica (PMR). Patho-
genesis of PMR is thought to be the result of the interaction between environ-
mental factors, possibly virus, and the innate immune system in genetically 
predisposed individuals. The senescence of the immune systems as demon-
strated by the loss of the CD28 on CD4+ T senescent cells may be responsible 
for aberrant immune responses in PMR. Adaptive immune alterations also oc-
curs in PMR mainly represented by the activation of Th17 cells, mainly driven 
by the increased IL-6 levels. An altered distribution and phenotype of B cells 
also occurs in PMR even in the absence of a clear autoimmune response. Lo-
cal activation of myeloid and endothelial cells has been also demonstrated in 
the non-inflamed arteries and inflamed synovial tissues of PMR patients.
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n	 INNATE IMMUNE RESPONSES
Despite the evidence that PMR causes 
severe pain and stiffness in the proximal 
muscle groups, there is no evidence of 
inflammation in muscle biopsy and elec-
tromyographic findings are normal (27, 
28). The inflammation in PMR patients 
has been demonstrated to occur at the 
level of the synovium and bursae associ-
ated with the shoulder and hip girdles, 
where the recognition of an unknown an-
tigen by dendritic cells or macrophages 
occurs (29, 30). The synovitis of PMR 
is characterized by vascular proliferation 
and leukocyte infiltration, predominantly 
macrophages and T lymphocytes (29, 31). 
A few neutrophils, but no B cells, natural 
killer cells, or gamma/delta T cells have 
been found. Intense expression of HLA 
class II antigens (DR more than DP more 
than DQ) was found in the lining layer 
cells as well as in macrophages and lym-
phocytes. Class II antigen expression cor-
related with the number of macrophages 
and lymphocytes (30). In patients with 
PMR, adventitial DCs, even in the ab-
sence of vasculitic infiltrates, have been 
demonstrated to be mature and to produce 
CCL19 and CCL21. When PMR arteries 
are transplanted in SCID mice, DCs at-
tract, retain, and activate T cells that origi-
nated from the GCA lesions (32). Beyond 
the presence of activated macrophages in 
the synovial and arterial samples of PMR 
patients, a systemic activation of circulat-
ing monocytes has been also demonstrat-
ed, mainly characterized by the increased 
IL-6 and IL-1 beta production (33). 
Toll-like receptors (TLRs) are expressed 
on many types of cells including mac-
rophages and dendritic cells (DCs) and 
play an essential role in the activation and 
regulation of innate immune responses 
through recognition of specific pathogen-
associated molecular patterns and endog-
enous peptides (34). Increased expression 
of Toll-like receptor (TLR) 7 and TLR 9, 
which resolves with complete disease re-
mission, has been demonstrated in the pe-
ripheral mononuclear blood cells of both 
PMR and GCA patients (18). However, al-
lele and genotype and haplotype analysis 
of TLR9 T1486C and T1237C revealed no 
significant association with PMR suscep-
tibility (19). 
In the healthy immune system, aberrant 
immune stimulation is avoided by negative 
co-stimulatory signals that protect tissue 
tolerance. Programmed cell death protein 
1, also known as PD-1 and CD279 (clus-
ter of differentiation 279), is a cell surface 
receptor that plays an important role in the 
regulation of immune system homeostasis 
by suppressing T cell inflammatory activi-
ties (35). PD-1 acts by promoting apoptosis 
in antigen specific T-cells in lymph nodes 
while simultaneously reducing apoptosis 
in regulatory T cells (anti-inflammatory, 
suppressive T cells) (35). A recent study 
demonstrated that GCA-affected temporal 
arteries have low expression of the co-in-
hibitory ligand programmed death ligand-1 
(PD-L1) concurrent with enrichment of the 
programmed death-1 (PD-1) receptor. In 
addition, tissue-residing and ex vivo-gen-
erated dendritic cells (DC) from GCA pa-
tients were PD-L1lo, whereas the majority 
of vasculitic T cells expressed PD-1, sug-
gesting inefficiency of the immunoprotec-
tive PD-1/PD-L1 immune checkpoint (36). 
Although the expression of the PD1/PDL1 
immune checkpoint has been never studied 
in PMR patients, several studies indicate 
the onset of PMR symptoms in patients 
treated with anti-PD1/anti-PDL-1 agents 
indicating a potential role of PD1/PDL1 
signal in PMR pathogenesis (37, 38).
n	 ADAPTIVE IMMUNE 
RESPONSES
Analysis of inflammatory cytokines ex-
pression in temporal artery tissues of GCA 
patients showed that in situ synthesis of 
interleukin-2 (IL-2), interferon-y (IFNy), 
and IL-1b mRNA, but not of IL-10 and 
IL-12 mRNA, distinguished different pat-
terns of inflammation correlated with dif-
ferent clinical disease manifestations (39). 
Patients with evidence of ischemic symp-
toms, indicated by jaw claudication and/
or visual symptoms, typically expressed 
higher concentrations of IFNy mRNA and 
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IL-1b mRNA (39). Presence of fever was 
correlated with lower copy numbers of 
IFNy. Formation of giant cells in the granu-
lomatous infiltrates was associated with the 
local synthesis of IFNy mRNA (39). Tissue 
from GCA patients with concomitant PMR 
contained higher levels of IL-2 mRNA 
transcripts (39). 
IL-6 is a cytokine displaying pleiotropic 
activity. IL-6 induces synthesis of acute 
phase proteins such as CRP, serum amy-
loid A, fibrinogen, and hepcidin in hepato-
cytes. IL-6 also plays an important role in 
acquired immune response by stimulation 
of antibody production and of effector T-
cell development such as Th17 cells (40). 
Patients with PMR often show elevated IL-
6, IL-1Ra and BAFF levels closely related 
with clinical symptoms (41-45). Cortico-
steroids rapidly suppress IL-6 production 
but do not correct the underlying mecha-
nism, inducing increased IL-6 production 
since short-term withdrawal of corticoste-
roids, even after several months of treat-
ment, is followed by an immediate increase 
in plasma IL-6 concentrations (44). In ad-
dition, most studies in PMR show that a de-
crease in the level of circulating IL-6 corre-
lates with remission of clinical symptoms 
and that high serum IL-6R levels combined 
with low haemoglobin values resulted in 
a ten-fold increased risk of PMR relapse 
(45). Boiardi et al. showed that the CC IL-6 
genotype characterized PMR patients with 
persistently elevated levels of IL-6 who are 
at higher risk of developing relapse/recur-
rence (17). Altogether, these findings indi-
cate that a genetically modulated pattern of 
IL-6 production could affect the long-term 
outcome of patients with PMR (17). Data 
on other circulating cytokines (e.g., IL-1, 
IL-2, TNF-alpha, IL-10) are too few to 
draw any conclusions.
According to the important role of IL-6 in 
modulating the function of effector Treg 
and Th17 cells, the disturbed IL-6 produc-
tion demonstrated in PMR should be as-
sociated with a disturbed effector T-cells 
distribution. Compared with control sub-
jects, patients with PMR have a decreased 
frequency of Treg cells, whereas the per-
centage of Th17 cells was significantly 
increased and reduced by glucocorticoid 
treatment (46). Although the frequency of 
CD161+CD4+ T-cells, which are consid-
ered to be Th17 cell precursors, is similar 
in patients and control subjects, their abil-
ity to produce interleukin-17 in vitro is sig-
nificantly enhanced in patients with PMR 
(46). Beyond the altered distribution of 
Treg/Th17 cells, Shimojima demonstrated 
a decrease in activated cytotoxic/suppres-
sor T-cells and increases in circulating Th1 
and Tc1 cells in PMR patients (47). A sig-
nificant decrease in absolute numbers and 
relative percentages of CD8+ T lympho-
cytes, inversely correlated with the acute 
hepatic phase reactants and modified by 
steroids treatment has been demonstrated 
in PMR patients (48-53). The studies per-
formed by Martinez-Taboada and co-work-
ers do not confirm, however, the previous 
findings that the proportion or number of 
circulating CD8+ T-cells are reduced in pa-
tients with active PMR (53). The Authors 
demonstrated that untreated PMR/GCA 
patients carried multiple clonally expanded 
CD8 populations. Molecular analysis of 
the CD8+ clonotypes showed a restricted 
TCR repertoire in the patients with a dis-
tinct Jbeta gene segment usage (54). Oli-
goclonality in the CD8 repertoire persisted 
despite successful control of the disease ac-
tivity, suggesting that the CD8+ clonotypes 
are not an epiphenomenon of the inflam-
mation (54). The same group demonstrated 
that the phenotype of circulating T-cells in 
patients with PMR/GCA is similar to that 
found in aged healthy subjects, except for 
the surface markers of naive and memory 
cells and a striking non-activated pheno-
type (55). In particular, Lopez-Hoyos and 
co-workers showed that specific TCR BV 
changes occur in patients with active dis-
ease accompanied by a significant decrease 
in certain TCRBV families in both CD4+ 
and CD8+ T-cell subsets, which may favour 
the participation of a superantigen stimula-
tion in PMR/GCA (54). In both GCA and 
PMR patients, NKG2D was preferentially 
expressed on senescent CD4 CD28(-) and 
CD8 CD28(-), as well as on CD8 CD28 T-
cells (55). Frequencies of senescent T-cells 
were increased in GCA and PMR patients 
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compared to HC. In GCA tissue samples, 
infiltrating T-cells were predominately 
CD28(-). 
NKG2D is a potent activating receptor ex-
pressed on virtually all NK cells, on most 
NKT cells and subpopulations of γδ T-
cells. All human CD8+ αb T-cells express 
NKG2D, whereas NKG2D expression on 
CD4+ αb T-cells has been reported only 
in pathological conditions (56). In both 
PMR patients, NKG2D is preferentially 
expressed on senescent CD4 CD28(-) and 
CD8 CD28(-), as well as on CD8 CD28 
T-cells and the frequencies of senescent T-
cells are increased in PMR patients. In the 
presence of antigenic stimulation, a rapid 
up-regulation of NKG2D on CD4 CD28(-
) and CD4 CD28 T-cells is observed. In-
terestingly, TNF-α and interleukin-15 en-
hanced NKG2D expression on senescent 
CD4 and CD8 T-cells only. Finally, NK-
G2D cross-linkage augmented anti-CD3 
triggered proliferation, IFN-γ and TNF-α 
production of CD8 T-cells (31). 
B-lymphocytes are crucial components 
of both innate and adaptive immunity. 
Although an autoimmune component has 
been never demonstrated in PMR patients, 
a decreased frequency of circulating B 
cell has been demonstrated in PMR, rap-
idly recovered after steroid treatment (57). 
Interestingly, in PMR the B cell numbers 
are inversely correlated with erythrocyte 
sedimentation rates, C-reactive protein 
levels, and serum BAFF levels. In par-
ticular, the frequency of Tumour necrosis 
factor α-positive Beff cells was decreased 
in patients newly diagnosed with PMR 
and normalized by steroid treatment (57). 
More recently, it has been demonstrated 
that B-cell lymphopenia and abnormal B-
cell subset distribution, associated with 
disease activity and IL-6 concentration, 
are corrected by the IL-6 antagonist tocili-
zumab (57).
n	 ENDOTHELIAL DYSFUNCTION 
IN POLYMYALGIA 
RHEUMATICA
Systemic inflammation in many human 
diseases has been associated with an im-
balance between endothelial injury and 
repair characterized by a reduced num-
ber of endothelial progenitor cells (EPCs) 
(58). Pirro and co-workers have recently 
studied the association between inflam-
mation and endothelial injury and repair 
in patients with PMR (59). 
The Authors demonstrated that PMR is 
associated with a significant imbalance 
between endothelial injury and repair, 
which is dependent on the degree of sys-
temic inflammation. 
In this study, levels of C-reactive protein 
(CRP) were associated with an increased 
circulating endothelial microparticles 
(EMP) EMP/EPC ratio, irrespective of 
traditional cardiovascular risk factors. 
Corticosteroid therapy led to a significant 
CRP reduction paralleled by a consistent 
decline in the EMP/EPC ratio (59). The 
occurrence of endothelial dysfunction in 
PMR is also suggested by the finding that 
VEGF serum concentrations are signifi-
cantly higher in untreated PMR. PBMC 
isolated from untreated PMR patients 
spontaneously secrete a higher amount of 
VEGF compared with PBMC from con-
trol subjects and corticosteroid therapy 
does not affect the ability of PBMC to 
produce VEGF. 
Immunohistochemical staining performed 
on shoulder synovial tissue showed VEGF 
expression in both the lining layer and the 
sublining area and was correlated with 
vessel density, but was not associated with 
alphavbeta3 and alphavbeta5 integrin ex-
press (60).
n	 CONCLUSIONS
The pathogenesis of PMR appears to be 
more complex than previously thought. 
Activation of innate and adaptive immune 
systems in response to unknown envi-
ronmental triggers appears to be the key 
pathogenetic mechanism in PMR. A role 
of B cells in modulating systemic immune 
responses in PMR appears to be also rele-
vant. Further studies are required, however, 
to clarify better the cascade of events that 
lead to aberrant activation of the immune 
system in PMR.
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